{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(12)"],"submitter":["Watanabe Y"],"pubmed_abstract":["<b><i>Background:</i></b> The Kumamoto criteria have been proposed as a non-invasive screen for transthyretin amyloid cardiomyopathy. This study assessed the validity of the Kumamoto criteria externally. <b><i>Methods and Results:</i></b> The study included 138 patients (median age 73 years; 65% male) who underwent <sup>99 m</sup>Tc-pyrophosphate (PYP) scintigraphy. Patients were divided into 4 groups according to total scores on the Kumamoto criteria (i.e., 0-3) for the following 3 factors: high-sensitivity cardiac troponin T ≥0.0308 ng/mL, wide (≥120 ms) QRS, and left ventricular posterior wall thickness ≥13.6 mm. The diagnostic performance and positive predictive value (PPV) of the Kumamoto criteria for positive <sup>99 m</sup>Tc-PYP scintigraphy were validated. Eighteen (13%) patients were positive on <sup>99 m</sup>Tc-PYP scintigraphy. The Kumamoto criteria had a favorable diagnostic performance (area under the curve 0.808). The PPV for groups with scores of 0, 1, 2, and 3 was 0% (n=0/42), 11% (n=6/57), 21% (n=7/33), and 83% (n=5/6), respectively, which is lower, particularly for those with a score of 2, than in the original Kumamoto cohort. However, the PPV increased after combining the Kumamoto criteria with a history of orthopedic diseases (spinal canal stenosis and/or carpal tunnel syndrome). <b><i>Conclusions:</i></b> This study suggests that the Kumamoto criteria have a favorable diagnostic performance; however, the PPV may decrease depending on the study population. Combining the Kumamoto criteria with the presence of orthopedic disease may improve the PPV."],"journal":["Circulation reports"],"pagination":["579-587"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9727327"],"repository":["biostudies-literature"],"pubmed_title":["External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening　- A Retrospective Cohort Study."],"pmcid":["PMC9727327"],"pubmed_authors":["Kunugi S","Imori Y","Watanabe Y","Murata H","Iwasaki YK","Kiriyama T","Nakano H","Takano H","Hachisuka M","Shimizu A","Uchiyama S","Kodani E","Shimizu W","Matsuda J","Yodogawa K"],"additional_accession":[]},"is_claimable":false,"name":"External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening　- A Retrospective Cohort Study.","description":"<b><i>Background:</i></b> The Kumamoto criteria have been proposed as a non-invasive screen for transthyretin amyloid cardiomyopathy. This study assessed the validity of the Kumamoto criteria externally. <b><i>Methods and Results:</i></b> The study included 138 patients (median age 73 years; 65% male) who underwent <sup>99 m</sup>Tc-pyrophosphate (PYP) scintigraphy. Patients were divided into 4 groups according to total scores on the Kumamoto criteria (i.e., 0-3) for the following 3 factors: high-sensitivity cardiac troponin T ≥0.0308 ng/mL, wide (≥120 ms) QRS, and left ventricular posterior wall thickness ≥13.6 mm. The diagnostic performance and positive predictive value (PPV) of the Kumamoto criteria for positive <sup>99 m</sup>Tc-PYP scintigraphy were validated. Eighteen (13%) patients were positive on <sup>99 m</sup>Tc-PYP scintigraphy. The Kumamoto criteria had a favorable diagnostic performance (area under the curve 0.808). The PPV for groups with scores of 0, 1, 2, and 3 was 0% (n=0/42), 11% (n=6/57), 21% (n=7/33), and 83% (n=5/6), respectively, which is lower, particularly for those with a score of 2, than in the original Kumamoto cohort. However, the PPV increased after combining the Kumamoto criteria with a history of orthopedic diseases (spinal canal stenosis and/or carpal tunnel syndrome). <b><i>Conclusions:</i></b> This study suggests that the Kumamoto criteria have a favorable diagnostic performance; however, the PPV may decrease depending on the study population. Combining the Kumamoto criteria with the presence of orthopedic disease may improve the PPV.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2024-10-19T06:44:06.084Z","creation":"2024-10-19T06:44:06.084Z"},"accession":"S-EPMC9727327","cross_references":{"pubmed":["36530839"],"doi":["10.1253/circrep.CR-22-0110"]}}